Viatris news and events in 2026
Viatris is a pharmaceutical and healthcare corporation that develops and supplies a variety of medical treatments. The organization maintains a portfolio that includes generic medications, established brands, and innovative medicines designed to address unmet therapeutic needs.
Public (VTRS)Pharmaceutical Manufacturing10,000+ employeesviatris.comLinkedIn
Get Viatris' live signals in Claude or ChatGPT, or by API
What changed at Viatris this week? Use Autobound signals for viatris.com.- Dated updates
- 73
- Last event
- Oct 30, 2026
- Open rolesSnapshot Nov 3, 2026
- 51
- Latest SEC filing
- Oct 8, 2026
Source: Autobound Signal API · 73 signals tracked for Viatris · updated
Overview
Viatris by topic
110-K filing
51open roles
1executive move
48+signals
20 in the last 90 days
- Glassdoor15+
- LinkedIn15+
- Website changes15+
- Patents2
- and 1 more sources
Latest events
Latest Viatris events
Showing 10 of 15 events. The Signal API returns all of them.
Get them with one API call- AcquisitionViatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.Viatris commenced a tender offer through its subsidiary Peach Purchaser Sub Inc. to acquire Pacira BioSciences for $36.50 per share in cash.
- AcquisitionViatris to Acquire Pacira BioSciences for $1.65 Billion, Expanding Non-Opioid Pain Portfolio$1.6B · With Pacira BioSciences Inc.
- Asset saleHarrow Closes Acquisition of TYRVAYA®Viatris Inc. has sold the worldwide rights (excluding Japan) for its TYRVAYA® nasal spray to Harrow for $30 million in cash, with potential for up to $70 million in additional milestone payments.
- Recognition
- New customer
- LaunchViatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea...Viatris announced that its drug WAKIX® (pitolisant) has received approval from Japan's Ministry of Health, Labour and Welfare for treating excessive daytime sleepiness associated with obstructive sleep apnea syndrome and for narcolepsy.
- EarningsViatris Lifts 2026 Outlook After Strong Second QuarterViatris reported an adjusted EBITDA of $1.2 billion for the second quarter of 2026, up 8% operationally.
- In developmentVTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape OutlookViatris anticipates the potential launch of its fast-acting meloxicam product.
- EarningsViatris Announces Quarterly DividendViatris Inc. declared a quarterly dividend of $0.12 per share.
- LaunchViatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive PatchViatris received U.S. FDA approval for Gwyn Lo, a new once-weekly combined hormonal contraceptive patch with low-dose estrogen.
Showing 10 of 15 events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Viatris with the Signal API
One POST /v1/companies/enrich call with viatris.com returns every signal type for Viatris, each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"viatris.com","limit":20}'Bulk data
Need these signals for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file).
Same industry
Companies related to Viatris
Viatris questions
What is the latest news on Viatris?
What is going on with Viatris?
Has Viatris announced any acquisitions?
What else does Autobound track for Viatris?
Is Viatris hiring right now?
Page updated , the date of the newest row on this page.
Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.
Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.
Data as of .